Skip to main content
. 2019 Apr 1;142(6):1767–1782. doi: 10.1093/brain/awz069

Table 1.

Demographic and clinical variables

Healthy controls (n = 18) Alzheimer’s disease (n = 27) LBD (n = 42) Between-group differences
Male: female 11:7 20:7 36:6 χ2 = 4.5, P = 0.11a
Age 76.3 (5.5) 74.9 (7.0) 74.8 (6.4) F(2,84) = 0.35, P = 0.70b
AChEI - 25 36 χ2 = 0.76, P = 0.38c
PD meds - 1 29 χ2 = 28.6, P < 0.001c
Duration - 3.9 (2.1)f 3.2 (2.1)g U = 399, P = 0.12d
MMSE 29.2 (0.9) 20.7 (4.3) 23.1 (3.7) t(67) = 2.51, P = 0.01e
CAMCOG 96.7 (3.7) 67.4 (15.7) 75.7 (11.1) t(67) = 2.57, P = 0.01e
UPDRS III 1.3 (1.5) 2.4 (3.0) 20.4 (8.5) t(67) = 10.6, P < 0.001e
CAF total - 0.38 (0.98)g 5.0 (4.3)h t(64) = 5.31, P < 0.001e
Mayo total - 9.4 (4.7)g 14.0 (5.7)h t(64) = 3.41, P = 0.001e
Mayo cogn - 1.9 (1.8)g 2.8 (1.8)h t(64) = 2.06, P = 0.043e
NPI total - 6.8 (6.6)g 14.3 (10.5)i t(65) = 3.23, P = 0.002e
NPI hall - 0.04 (0.20)g 1.9 (2.0)i t(65) = 4.90, P < 0.001e

Values are mean (SD).

AChEI = number of patients taking acetylcholinesterase inhibitors; CAF total = Clinician Assessment of Fluctuation total score; CAMCOG = Cambridge Cognitive Examination; Duration = duration of cognitive symptoms in years; LBD = Lewy body dementia; Mayo total = Mayo Fluctuations Scale; Mayo cognitive = Mayo Fluctuation cognitive subscale; MMSE = Mini-Mental State Examination; PD meds = number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms; UPDRS III = Unified Parkinson’s Disease Rating Scale III (motor subsection); NPI = Neuropsychiatric Inventory; NPI hall = NPI hallucination subscore.

aChi-square test healthy controls, Alzheimer’s disease, Lewy body dementia.

bOne-way ANOVA healthy controls, Alzheimer’s disease, Lewy body dementia.

cChi-square test Alzheimer’s disease, Lewy body dementia.

dMann Whitney U-test Alzheimer’s disease, Lewy body dementia.

eStudent’s t-test Alzheimer’s disease, Lewy body dementia.

f n = 25, gn = 26, hn = 40, in = 41.